H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage of Affimed with a Buy rating and $6 price target. Affimed is a clinical-stage biotechnology company focused on developing innate cell engagers for the treatment of cancer, Ramakanth tells investors in a research note. The analyst believes AFM13 and AFM24 "could unleash the therapeutic potential of innate immune cells across multiple solid and liquid tumors."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AFMD:
- Affimed Plunges after Detailing New Plans
- Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting
- Piper Sandler keeps Overweight rating on Affimed, lowers price target to $6
- Affimed provides data from Phase 1/2 study AFM13 precomplexed with cbNK cells
- Affimed reports topline data from AFM13 monotherapy Phase 2 REDIRECT study
